JPH10237045A - Hapten compound of triflumizole, antibody and measurement - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain an antibody specific to triflumizole by utilizing, as a hapten, an triflumizole derivative that is prepared by introducing a spacer arm and a functional group to be used in bonding to a macromolecule into triflumizole. SOLUTION: The derivative to be used as a hapten for preparing an antibody has a structure of' formula I (n is an integer of 1-10) and is prepared, for example, by removing the benzyl protection group from an imidobenzyl ester of formula II. The compound of formula I is linked to a macromolecular compound to form an antigen and this antigen is used to produce an antigen that is reactive with triflumizole having the chemical structure of formula III or its fragment. Thus, triflumizole having a wide range of antimicrobial activity becomes determinable in environment and in food products.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

The present invention relates to (E) -4-chloro-α, α, α-trifluoro-N- (1-imidazole-
The present invention relates to a hapten compound, an antigen, an antibody and a fragment thereof of 1-yl-2-propoxyethylidene) -o-toluidine (hereinafter, referred to as "triflumizole" in the present specification).

[0002] The present invention further relates to an immunoassay method using the above antigen, antibody and fragment thereof.

[0003]

2. Description of the Related Art Triflumizole has the following formula (2):

Embedded image And belongs to the imidazole-based ergosterol biosynthesis inhibitor (hereinafter, referred to as “EBI agent”).

[0004] Ergosterol is one of the sterols synthesized in the body by many filamentous fungi except algae, and is present between the bilayers of the phospholipids of biological membranes, and the strength and permeability of cell membranes Has an important effect on the function of various membrane enzymes. Ergosterol is synthesized in vivo from acetic acid via mevalonic acid, squalene, and the like, and a group of compounds that specifically inhibit any reaction of this pathway is generically referred to as an EBI agent. EBI agents have a wide antimicrobial spectrum and excellent properties such as permeability and therapeutic properties. It is effective against ascomycetes, basidiomycetes, incomplete fungi, etc., and is particularly characterized by having an excellent effect on powdery mildew of various crops. Compared to conventional drugs, it is effective at lower doses and penetrates quickly into the plant body, so it has rain resistance. In addition, since it has low toxicity to insects visiting flowers such as bees, it can be sprayed during flowering of fruit trees and the like. EBI agents are classified into triazoles, imidazoles, pyrimidines and the like based on their chemical structures. The triflumizole of the present invention belongs to the imidazole-based EBI agent among these (Agrochemical Handbook No. 2
P.24-p.231 1994 Japan Plant Protection Association).

Triflumizole has a broad antibacterial activity and is effective against a wide range of diseases such as apple and pear scab, scab, powdery mildew of vegetables and the like, and rice and wheat seed infectious diseases. It has preventive and therapeutic effects. It is relatively weak to migrate in plants, while it has a gas effect. Like other EBI agents, it does not inhibit fungal spore germination but inhibits hyphal elongation, lesion formation, expansion, and spore formation. In addition to being used as a foliage spray, it is also used as a seed disinfectant and smoker (Agrochemical Handbook, pp. 230-231).

[0006] In recent years, there has been a great social interest in pesticide residues in environments such as soil, water, and the atmosphere, and in residues of post-harvest pesticides in imported agricultural products, which have recently increased in particular. Regarding triflumizole, the residue standard value based on the Food Sanitation Law is 1.0 p for cereals such as wheat and corn.
pm, vegetables, such as radish, radish, carrot, 1.0p
2.0 pp for fruits such as pm, tangerines, apples and strawberries
(Agricultural Chemical Registration Reservation Standards, Pesticide Residue Standards Handbook, Pesticide Environmental Conservation Measures Study Group, pp. 559-564). In order to ensure the safety of the environment and foods, it is necessary to measure the amount of triflumizole contained therein quickly and accurately.

Conventionally, triflumizole has been used for cereals, fruits,
After extraction and purification from samples such as vegetables and matcha, it has been analyzed by high performance liquid chromatography (HPLC). For example, after extracting a sample with methanol, purifying with dichloromethane transfer solution and column chromatography,
The method of analyzing by PLC has been adopted. In these methods, preparation of the sample is complicated and requires a great deal of labor and time,
There are problems such as having a high skill in analysis and requiring high cost for measuring devices and equipment. Measurement of triflumizole requires analysis of a huge number of samples in a short period of time, especially in the analysis of residual agricultural chemicals such as imported agricultural products, and is not only accurate, but also simple, quick and economical. There has been a demand for a new measurement method that also has the following.

The immunological assay is a method for detecting an antigen based on an antigen-antibody reaction in which the antibody specifically recognizes the antigen. Due to its excellent accuracy, simplicity, rapidity, and economic efficiency, the immunological assay has recently been carried out. It's getting attention. In immunoassays, a great variety of labels have been applied as detection methods, for example enzymes, radiotracers, chemiluminescent or fluorescent substances, metal atoms, sols, latexes and bacteriophages.

Among the immunoassays, enzyme immunoassay (EIA) using an enzyme has been widely used as a particularly excellent one. An excellent review of enzyme immunoassays can be found in Tijssen P, “Practice and theory of e
nzyme immunoassays "in Laboratory techniques in bi
ochemistry and molecular biology, Elsevier Amsterd
am New York, Oxford ISBN 0-7204-4200-1 (1990).

Generally, for a molecule having a large molecular weight,
By inoculating animals without further modification,
An appropriate immune response can be elicited to produce an antibody that recognizes the antigen. However, small molecules such as triflumizole usually fail to elicit an immune response when inoculated into animals. For the first time, these molecules act as a panel of epitopes by binding to immunogenic macromolecules and elicit an immune response in the presence of the T cell receptor, resulting in the production of antibodies by a group of B lymphocytes. Is done. Molecules that produce immunogenicity only when bound to a polymer compound in this way are collectively called “haptens”.

However, even when a low molecular compound is combined with a high molecular compound as an antigen, the resulting antibody often does not recognize the desired molecule or has only a very low affinity. Therefore, it is generally necessary to use not a low molecular compound itself but a hapten into which a spacer arm (bond) is introduced together with a functional group available for bonding. However, in such a case, a preferable antibody cannot be obtained unless one having been appropriately introduced in consideration of all problems such as the arrangement of the bond / functional group and the size of the bond is used. Appropriate introduction must be devised for each molecule.

[0012] Despite the extremely high need for triflumizole, no hapten for producing the antibody as well as a suitable antibody had been obtained before the present invention.

[0013]

SUMMARY OF THE INVENTION An object of the present invention is to provide a derivative of a compound which is a hapten compound constituting an antigen for producing a novel antibody specifically reacting with triflumizole. I do.

Another object of the present invention is to provide a conjugate of a triflumizole derivative and a polymer compound. The conjugate serves as an antigen for producing an antibody that specifically reacts with triflumizole.

Another object of the present invention is to provide a novel antibody or a fragment thereof having a strong novelty with triflumizole, and a method for producing the same.
As used herein, the term “fragment” of an antibody means a part of an antibody capable of binding to an antigen, for example, a _Fab fragment or the like.

[0016] In one aspect, the present invention provides a monoclonal antibody reactive with the compound.

Another object of the present invention is to provide a hybridoma that produces the antibody and its fragment.

Another object of the present invention is to provide a method for immunological measurement of triflumizole, which comprises using the above antibody.

[0019]

Means for Solving the Problems As a result of intensive studies, the present inventors have found that a derivative of triflumizole obtained by introducing a functional group available for binding to a spacer arm and a polymer into triflumizole is a hapten derivative. By using as, succeeded in obtaining an antibody specific to the compound,
The present invention has been completed.

The triflumizole that is the object of the present invention is
The following equation (2):

Embedded image It is a compound represented by these.

A derivative used as a hapten for producing an antibody is the above-mentioned triflumizole.

Embedded image Part of

Embedded image [Wherein, n is an integer of 1-10, preferably 2-5
). That is, the triflumizole derivative of the present invention has the following formula (1):

Embedded image [In the formula (1), n is as described above].

By using, as an antigen, a derivative obtained by binding a spacer arm and a functional group available for binding to the triflumizole of the present invention to a suitable polymer compound as a hapten, an antigen specific to triflumizole can be obtained. Antibody can be obtained.

The present invention relates to the hapten compound, a conjugate of the hapten compound and a polymer compound, an antibody reacting with triflumizole, a method for producing the same, and immunological analysis of the hapten compound or triflumizole using the antibody. Related to the measurement method.

Preparation of Derivatives of Triflumizole The triflumizole derivative represented by the formula (1) is, for example, represented by the formula (3):

Embedded image Wherein X is a hydrogen atom or a p-methoxy group, and n is as defined above. From the imide benzyl ester compound of formula (1), by removing the benzyl group of the protecting group.

The removal of the benzyl group can be carried out by a catalytic reduction reaction with hydrogen. The reduction reaction is carried out in the presence of a catalyst such as Pd-C, in the presence or absence of equimolar or more of hydrogen chloride, in a solvent such as water, methanol, ethanol, N, N-dimethylformamide, ethyl acetate, acetic acid, or In these mixed solvents, the reaction is carried out under normal pressure or under pressure.
0 ° C to the boiling point of the solvent, preferably room temperature to 50 ° C
The compound of formula (1) can be obtained by stirring and reacting at a temperature of 1 to 30 hours, preferably 2 to 15 hours.

The benzyl ester compound represented by the formula (3) can be synthesized, for example, according to the following method.

First, 4-chloro-2-trifluoromethylaniline has the following formula (Z1):

Embedded image [R ′ is a lower alkyl group, and n is as defined above. Carboxylic acid chloride represented by the following formula: benzene, toluene, xylene, dichloromethane, chloroform, carbon tetrachloride, diethyl ether, tetrahydrofuran, dioxane, acetone, methyl ethyl ketone, acetonitrile, ethyl acetate, dimethylformamide, dimethyl sulfoxide, etc. By stirring and reacting in a solvent in the presence or absence of an inorganic base such as sodium bicarbonate or potassium bicarbonate, or an organic base such as triethylamine, pyridine or diisopropylethylamine, the following formula (Z2):

Embedded image [Wherein, R ′ and n are as defined above. An amide ester compound represented by the following formula:
The reaction is carried out at a temperature from 0 ° C. to the boiling point of the solvent, preferably from room temperature to 50 ° C., for 5 minutes to 10 hours, preferably 1-3 hours.

The starting material carboxylic acid chloride (Z1) is
It can be synthesized by chlorinating the corresponding carboxylic acid with an acid chlorinating agent such as thionyl chloride, phosphorus trichloride, phosphorus pentachloride and the like.

Next, the amide ester compound of the formula (Z2) is preferably dissolved in an organic solvent such as methanol, ethanol, tetrahydrofuran, ethylene glycol or the like. The solvent is stirred at a temperature of the boiling point of the solvent, preferably from room temperature to 50 ° C., for 5 minutes to 5 hours, preferably 30 minutes to 1 hour to obtain the following formula (Z3):

Embedded image [Wherein, n is as defined above. ] Can be obtained. In the present compound, the compound in which n is 2 or 3 can also be obtained by reacting 4-chloro-2-trifluoromethylaniline with succinic anhydride or glutaric anhydride.

Next, the carboxylic acid compound of the formula (Z3) is converted into a carboxylic acid chloride with an acid chlorinating agent such as thionyl chloride, phosphorus trichloride, phosphorus pentachloride, etc. In the method, the following formula (Z4):

Embedded image [Wherein, X is as defined above. And benzyl alcohol represented by the following formula (Z5):

Embedded image [Wherein, X 1 and n are as defined above. An amide benzyl ester compound represented by the following formula:

Next, this benzyl ester compound is disclosed in Japanese Patent Laid-Open Publication Nos. 53-15372 or 54-119.
The chlorination is carried out in the same manner as described in No. 462, and the following formula (Z6):

Embedded image Wherein X and n are as defined above. And then reacted with imidazole in the same manner as in the same specification to obtain an imide benzyl ester compound represented by the general formula (2).

The preparation of the antigen and the antibody of the present invention and the method for immunological measurement will be described below. In addition, these preparations can be carried out according to a known method, for example, a method described in Seikagaku Experimental Lecture, Immunobiochemical Research Method (edited by the Japanese Biochemical Society), or the like.

Triflumizole derivative and polymer compound
Preparation of the conjugate The triflumizole derivative synthesized as described above is bound to an appropriate polymer compound and then used as an antigen for immunization.

Examples of preferred high molecular compounds include keyhole limpet hemocyanin (hereinafter referred to as “KLH”), ovalbumin (hereinafter referred to as “OVA”), bovine serum albumin (hereinafter referred to as “BSA”), Rabbit serum albumin (hereinafter referred to as "RSA") and the like, but KLH
And BSA are preferred.

The binding between the triflumizole derivative and the polymer compound can be carried out, for example, by the mixed acid anhydride method (BFErlanger et al.).
al .: J. Biol. Chem. 234 1090-1094 (1954)) or the activated ester method (AE KARU et al .: J. Agric. Food Che
m. 42 301-309 (1994)).

The mixed acid anhydride used in the mixed acid anhydride method is obtained by a usual Schotten-Baumann reaction, and this is reacted with a high molecular compound to produce a desired hapten-high molecular compound conjugate. You. The Schotten-Baumann reaction is performed in the presence of a basic compound. As the basic compound, a compound commonly used in the Schotten-Baumann reaction can be used.
For example, tributylamine, triethylamine, trimethylamine, N-methylmorpholine, pyridine, N, N
-Organic bases such as dimethylaniline, DBN, DBU and DABCO, and inorganic bases such as potassium carbonate, sodium carbonate, potassium hydrogencarbonate and sodium hydrogencarbonate. The reaction is usually performed at minus 20 ° C to 100 ° C, preferably at 0 ° C to 50 ° C, and the reaction time is 5 minutes-1.
0 hours, preferably 5 minutes to 2 hours. The reaction between the obtained mixed acid anhydride and the polymer compound is usually carried out at minus 20.
C. to 150.degree. C., preferably 0.degree. C. to 100.degree. C., and the reaction time is 5 minutes to 10 hours, preferably 5 minutes to 5 hours. The mixed anhydride method is generally performed in a solvent.
As the solvent, any solvent commonly used in the mixed acid anhydride method can be used, and specifically, ethers such as dioxane, diethyl ether, tetrahydrofuran, and dimethoxyethane, and halogenated solvents such as dichloromethane, chloroform, and dichloroethane. Hydrocarbons, aromatic hydrocarbons such as benzene, toluene and xylene, esters such as methyl acetate and ethyl acetate, aprotic polar solvents such as N, N-dimethylformamide, dimethyl sulfoxide, hexamethylphosphoric triamide, etc. Is mentioned. Examples of the haloformate used in the mixed acid anhydride method include, for example, isobutyl chloroformate, methyl chloroformate,
Examples thereof include methyl bromoformate, ethyl chloroformate, and ethyl bromoformate. The proportions of the hapten, the haloformate and the polymer compound used in the method can be appropriately selected from a wide range.

On the other hand, the activated ester method can be generally carried out as follows. First, a hapten compound is dissolved in an organic solvent and reacted with N-hydroxysuccinimide in the presence of a coupling agent to produce an N-hydroxysuccinimide ester.

As the coupling agent, an ordinary coupling agent commonly used for a condensation reaction can be used.
Dicyclohexylcarbodiimide, carbonyldiimidazole, water-soluble carbodiimide and the like. Examples of the organic solvent include N, N-dimethylformamide (D
MF), dimethyl sulfoxide (DMSO), dioxane and the like can be used. Hapten compound used in the reaction and N
The molar ratio of -hydroxysuccinimide is preferably 1:
10-10: 1, more preferably 1: 1-1: 10,
Most preferably, it is 1: 1. The reaction temperature is 0-100
° C, preferably 5-50 ° C, more preferably 22-27.
C., the reaction time is 5 minutes to 24 hours, preferably 30 minutes
6 hours, more preferably 1-2 hours. The reaction can be carried out at a temperature from the melting point to the boiling point.

After the coupling reaction, the reaction solution is centrifuged, and the supernatant is added to a solution in which the high molecular compound is dissolved to cause a reaction.
For example, when the polymer compound has a free amino group, an acid amide bond is generated between the amino group and the carboxyl group of the hapten compound. The reaction temperature is 0-60 ° C, preferably 5-40 ° C, more preferably 22-27 ° C,
The reaction time is 5 minutes to 24 hours, preferably 1 to 16 hours,
More preferably, it is 1-2 hours. The reaction product can be purified by dialysis, a desalting column or the like to obtain a conjugate of the triflumizole derivative and the polymer compound.

Further, a substance obtained by binding a labeling substance such as an enzyme to a triflumizole derivative by the same method as described above can be used in an immunological assay. Labeling substances include horseradish peroxidase (hereinafter, referred to as
"HRP"), enzymes such as alkaline phosphatase, chromogenic substances such as fluorescein isothiocyanate and rhodamine, radioactive substances such as ³² P and ¹²⁵ I, and chemiluminescent substances.

Preparation of Polyclonal Antibody The polyclonal antibody of the present invention can be prepared by a conventional method using a conjugate of a triflumizole derivative and a polymer compound. For example, a triflumizole derivative-KLH conjugate is added to a phosphate buffer (hereinafter referred to as “P
BS) and immunizing animals with a mixture of Freund's complete adjuvant or incomplete adjuvant, or an adjuvant such as alum. As the animal to be immunized, any of those commonly used in the art can be used, and examples thereof include mice, rats, rabbits, goats, and horses.

The administration method upon immunization may be any of subcutaneous injection, intraperitoneal injection, intravenous injection, subcutaneous injection, and intramuscular injection, but subcutaneous injection or intraperitoneal injection is preferred. Administration can be performed once or at appropriate intervals, preferably multiple times at intervals of one to five weeks.

Blood is collected from the immunized animal, and serum separated therefrom can be used to evaluate the presence of a polyclonal antibody that reacts with triflumizole.

Preparation of Monoclonal Antibody A monoclonal antibody of the present invention can be prepared by a known method using a conjugate of a triflumizole derivative and a polymer compound.

In preparing a monoclonal antibody,
At least the following work steps are required.

(A) Preparation of a conjugate of a triflumizole derivative and a polymer compound to be used as an antigen for immunization (b) Immunization of animals (c) Collection of blood, assay, and preparation of antibody-producing cells (d) ) Preparation of myeloma cells (e) Cell fusion between antibody-producing cells and myeloma cells and selective culture of hybridomas (f) Screening and cloning of hybridomas producing the desired antibody (g) Culture of hybridomas or animal cultivation Preparation of Monoclonal Antibody by Transplantation of Hybridoma (h) Measurement of Reactivity of Prepared Monoclonal Antibody, etc. Conventional methods for producing a hybridoma producing a monoclonal antibody include, for example, Hybridoma Techniques, Cold Spring
Harbor Laboratories (Cold Spring Harbor Laborat
ory), 1980 edition), cell histochemistry (Syuji Yamashita et al.,
Japan Society for Histocellular Chemistry; Interdisciplinary Project, 1986).

Hereinafter, a method for preparing the above-mentioned monoclonal antibody against triflumizole of the present invention will be described, but it will be apparent to those skilled in the art that the present invention is not limited thereto.

The steps (a) and (b) can be carried out by substantially the same method as described for the polyclonal antibody.

The antibody-producing cells in the step (c) are lymphocytes, which can be generally obtained from the spleen, thymus, lymph nodes, peripheral blood or a combination thereof, but spleen cells are most commonly used. . Therefore, after the final immunization, a site where antibody-producing cells are present, for example, a spleen is excised from a mouse in which antibody production has been confirmed, and splenocytes are prepared.

Examples of myeloma cells that can be used in the step (d) include, for example, P3 / X63-Ag8 (X63) (Natur
e, 25 6, 495-497 (1975 )), P3 / X63-Ag8. U
1 (P3U1) (Current Topics.in Microbiology and
Immunology, 81 1-7 (1987)), P3 / NSI-1-A
g4-1 (NS-1) (Eur. J. Immunol., 6 , 511-519)
(1976)), Sp2 / 0-Ag14 (Sp2 / 0) (Natu
re 276 , 269-270 (1978)), FO (J. Immuno. Meth., 3
5 , 1-21 (1980)), MPC-11, X63.653, S
Myeloma cell line such as 194, or 21 derived from rat.
0. RCY3. Ag 1.2.3. (Y3) (Nature 277 , 1
31-133, (1979)).

The above-mentioned cell line is subcultured in Dulbecco's modified Eagle's medium (DMEM) or Iscove's modified Dulbecco's medium (IMDM) containing fetal bovine serum, and a cell number of about 3 × 10 ³ or more is secured on the day of the fusion. .

The cell fusion in the step (e) is performed by a known method, for example, the method of Milstein et al.
Enzymology, 73 , 3 (1981)). The most commonly used method at present is a method using polyethylene glycol (PEG). For the PEG method, for example, cell histochemistry, Shuji Yamashita et al. (Described above)
It is described in. As another fusion method, a method by electric treatment (electric fusion) can be adopted (Etsuko Okochi et al., Experimental Medicine 5.1315-19, 198).
7). Other methods can be appropriately adopted. Also, the ratio of cells used may be the same as in the known method. For example, spleen cells may be used about 3 to 10 times as much as myeloma cells.

The selection of a hybridoma group in which spleen cells and myeloma cells are fused to obtain antibody-producing ability and proliferative ability is carried out, for example, when a hypoxanzing anidine phosphoribosyltransferase-deficient strain is used as a myeloma cell strain, as described above. It can be performed by using a HAT medium prepared by adding hypoxanthine / aminopterin / thymidine to DMEM or IMDM.

In the step (f), a part of the culture supernatant containing the selected hybridoma group is taken, and for example, E
The antibody activity against triflumizole is measured by the LISA method.

Further, cell cloning of a hybridoma which has been found by measurement to produce an antibody reactive with triflumizole is performed. As the cell cloning method, a method of limiting the dilution so that one hybridoma is contained in one well by limiting dilution “Limiting dilution method”; a method of collecting a colony spread on a soft agar medium; and a method of separating one cell by a micromanipulator Extraction method: a "sorter clone method" in which one cell is separated by a cell sorter, and the like. The limiting dilution method is simple and often used.

For the wells in which the antibody titer has been recognized, cell cloning is repeated 1-4 times, for example, by the limiting dilution method, and those with a stable antibody titer are selected as anti-triflumizole monoclonal antibody-producing hybridoma strains. . As a medium for culturing the hybridoma, for example, DMEM or IMDM containing 10% fetal bovine serum is used. The hybridoma is preferably cultured, for example, at a carbon dioxide concentration of about 5 to 7% and at 37 ° C. (in a thermostat at 100% humidity).

The mass culture for preparing the antibody in the step (g) is performed by a follow-fiber type culture apparatus or the like. Alternatively, mice of the same strain (for example, Bal
b / c) or hybridomas can be grown in the peritoneal cavity of Nu / Nu mice, and antibodies can be prepared from ascites fluid.

The culture supernatant or ascites fluid obtained as described above can be used as an anti-triflumizole monoclonal antibody. The antibody fraction is further subjected to dialysis, salting out with ammonium sulfate, gel filtration, freeze-drying, etc. By collecting and purifying, an anti-triflumizole monoclonal antibody can be obtained. If a higher degree of purification is required, it can be carried out by combining commonly used methods such as ion exchange column chromatography, affinity chromatography, and high performance liquid chromatography (HPLC).

The anti-triflumizole monoclonal antibody obtained as described above is used, for example, in the ELISA described below.
The subclass, antibody titer, and the like can be determined using a known method such as a method.

Measurement of Triflumizole by Antibody As a method of measuring triflumizole by the antibody used in the present invention, a radioisotope immunoassay (RIA) is used.
Method), ELISA method (Engvall, E., Methods in Enzymo
l., 70 , 419-439 (1980)), fluorescent antibody method, plaque method,
Spot method, agglutination method, octalony (Ouchterl
ony) method and other commonly used methods for detecting antigens ("hybridoma method and monoclonal antibody",
Published by R & D Planning Inc., pp. 30-53,
March 5, 1982). The ELISA method is widely used from the viewpoints of sensitivity, simplicity, and the like.

The measurement of triflumizole was performed by various ELISAs.
Among the methods, for example, indirect competitive inhibition ELISA can be performed by the following procedures. (A) First,
A conjugate of a triflumizole derivative as an antigen and a polymer compound is immobilized on a carrier. (B) blocking the surface of the solid phase on which the antigen is not adsorbed by a protein unrelated to the antigen, for example, a protein; (C) a sample and an antibody containing various concentrations of triflumizole are added thereto, and the antibody is allowed to react competitively with the immobilized antigen and free triflumizole,
An immobilized antigen-antibody complex and a free triflumizole-antibody complex are generated. (D) By measuring the amount of the immobilized antigen-antibody complex, the amount of free triflumizole in the sample can be determined from a previously prepared calibration curve.

In step (a), the carrier on which the antigen is immobilized is not particularly limited, and any carrier commonly used in the ELISA method can be used. An example is a 96-well microtiter plate made of polystyrene.

For immobilizing an antigen on a carrier, for example,
A buffer containing an antigen may be placed on a carrier and incubated. Known buffers can be used as the buffer, for example, 10 mM PBS containing 145 mM NaCl. The concentration of the antigen in the buffer can be selected from a wide range, but is usually about 0.01 to 100 μg / ml, preferably 0.05 to 5 μg / ml.
When a 96-well microtiter plate is used as a carrier, the concentration of 20 μl / well is not more than 300 μl / well.
Desirably about -150 μl / well. Furthermore, the conditions for incubation are not particularly limited, but usually incubation at about 4 ° C. overnight is suitable.

In the blocking in the step (b), the carrier to which the antigen (combination of the triflumizole derivative and the polymer compound) is immobilized can adsorb an antibody to be added later in addition to the triflumizole derivative portion. Parts may be present and are used solely to prevent them. As a blocking agent, for example, BSA or skim milk solution can be used. Or, Block Ace ("Block
Ace ", manufactured by Dainippon Pharmaceutical Co., Ltd., code No. UK-25
A commercially available blocking agent such as B) can also be used. Specifically, the method is carried out by, for example, but not limited to, adding an appropriate amount of Block Ace to a portion where the antigen is immobilized, incubating at about 4 ° C. overnight, and then washing with a buffer. The buffer is not particularly limited. For example, 10 mM PBS (p
H7.2), 0.8% (w / v) NaCl, 0.02%
(W / v) KCl, 0.02% (v / v) Tween2
A composition of 0 is suitable.

Next, in step (c), the sample containing triflumizole and the antibody are brought into contact with the immobilized antigen, and the antibody is reacted with the immobilized antigen and free triflumizole. The conjugate and free triflumizole-antibody conjugate are formed.

At this time, as the antibody, an antibody against the triflumizole of the present invention is added as a first antibody, and an antibody against the first antibody to which a labeling substance is bound is sequentially added as a second antibody to react.

The first antibody is dissolved in a buffer and added. Although not limited, the reaction may be performed at about 37 ° C. for about 1 hour. After the reaction is completed, the carrier is washed with a buffer to remove unreacted first antibody. The reagent used for this reaction was 10 mM PBS (pH 7.2), 0.8% (w /
v) NaCl, a composition of 0.02% (w / v) KCl is preferred.

Next, a second antibody is added. For example, when a mouse monoclonal antibody is used as the first antibody, it is appropriate to use an anti-mouse antibody-goat antibody conjugated with an enzyme (for example, peroxidase or alkaline phosphatase). About 5000-1 for the first antibody bound to the carrier
It is desirable to react the second antibody diluted so as to have a final absorbance of 0000-fold, preferably 1.0-1.5. Buffer is used for dilution. The reaction is carried out, but not limited to, at about 37 ° C. for about 1 hour, followed by washing with a buffer after the reaction. By the above reaction, the second antibody binds to the first antibody. Alternatively, a labeled first antibody may be used, in which case the second antibody is not required.

Next, in step (d), a chromogenic substrate solution that reacts with the labeling substance of the second antibody bound to the carrier is added, and the amount of triflumizole can be calculated from the calibration curve by measuring the absorbance.

When peroxidase is used as an enzyme that binds to the second antibody, for example, hydrogen peroxide is used as a substrate, and o-phenylenediamine (hereinafter, referred to as a color developing reagent).
"OPD"). Although not limited, the color reaction solution is added and reacted at about 25 ° C. for about 20 minutes, and then the enzyme reaction is stopped by adding 2N sulfuric acid. If OPD is used, measure the absorbance at 490 nm. On the other hand, when alkaline phosphatase is used as the enzyme that binds to the second antibody, the color is developed using, for example, p-nitrophenyl phosphate as a substrate, the enzyme reaction is stopped by adding 2N NaOH, and the absorbance at 415 nm is measured. The method is suitable.

With respect to the absorbance of the reaction solution to which free triflumizole was not added, the rate of decrease in the absorbance of the solution in which triflumizole was added and reacted with the antibody was calculated as the inhibition rate. Using a calibration curve prepared in advance based on the inhibition rate of the reaction solution to which triflumizole of known concentration was added,
The concentration of triflumizole in the sample can be calculated.

Alternatively, the measurement of triflumizole can be carried out, for example, by a direct competitive inhibition ELISA method using the monoclonal antibody of the present invention as described below.

(A) First, the monoclonal antibody of the present invention is immobilized on a carrier.

(B) The surface of the carrier on which the antibody is not immobilized is blocked by a protein unrelated to the antigen, for example, a protein.

(C) Separately from the above steps, a mixture is prepared by adding an enzyme-bound hapten obtained by binding a triflumizole derivative to an enzyme to a sample containing various concentrations of triflumizole.

(D) The mixture is reacted with the antibody-immobilized carrier.

(E) By measuring the amount of the immobilized antibody-enzyme-bound hapten complex, the amount of triflumizole in the sample is determined from a previously prepared calibration curve.

The carrier on which the monoclonal antibody is immobilized in the step (a) is not particularly limited and may be an ELISA.
Conventional methods can be used, and examples include a 96-well microtiter plate.
The immobilization of the monoclonal antibody can be carried out, for example, by placing a buffer containing the monoclonal antibody on a carrier and incubating. The composition and concentration of the buffer can be the same as in the indirect competitive inhibition ELISA method described above. Alternatively, a product obtained by binding an antibody to an amino group-bonded microtiter plate using a chemical bonding method can be used.

In the blocking in the step (b), the carrier on which the antibody is immobilized may have a portion where triflumizole and enzyme-bound hapten in the sample to be added later are adsorbed independently of the antigen-antibody reaction. It is done to prevent it. As the blocking agent and the method therefor, those similar to the indirect competitive inhibition ELISA method described above can be used.

The preparation of the enzyme-bound hapten used in the step (c) may be carried out by any method without particular limitation as long as it is a method of binding a triflumizole derivative to an enzyme. For example, the activated ester method described above can be employed. The prepared enzyme-linked hapten is mixed with a sample containing triflumizole.

In the step (d), the mixture is brought into contact with an antibody-immobilized carrier, and a complex of the antibody and the immobilized antibody is formed by a competitive inhibition reaction between triflumizole and the enzyme-bound hapten in the mixture. . The sample containing triflumizole is used after being diluted with an appropriate buffer. Without limitation, the reaction is performed, for example, at room temperature for about 1 hour. After the reaction, the carrier is washed with a buffer to remove unreacted enzyme-bound hapten. As the washing solution, for example, PBS can be used.

Further, in step (e), a chromogenic substrate solution which reacts with the enzyme of the enzyme-bound hapten is added in the same manner as in the indirect competitive inhibition ELISA method, and the amount of triflumizole is calculated from the calibration curve by measuring the absorbance. can do.

The monoclonal antibody TFZ6-1 of the present invention
2 shows that triflumizole is 0.01-100 ng / ml, preferably 1-1, by direct competitive inhibition ELISA.
It can be measured in the range of 00 ng / ml (Example 8, FIG. 1). Monoclonal antibody TFZ6-12 is very specific, reacting only with triflumizole,
It does not react with other azole compounds such as diniconazole, imazalil and diclobutrazole (Example 9, FIG. 2).

Hereinafter, the present invention will be described in detail with reference to Examples, but these are not intended to limit the technical scope of the present invention. Those skilled in the art can easily modify and change the present invention based on the description in the present specification, and they are included in the technical scope of the present invention.

[0085]

EXAMPLES Example 1 Synthesis of Triflumizole Derivative

Embedded image

5- (4-chloro-2-trifluoromethyl)
Luanilinocarbonyl) pentanoic acid ethyl ester
Synthesis of (2) Adipic acid monoethyl ester (1) (17.4 g, 0.1 mol) and thionyl chloride (20.5 g, 0.15 mol) were added to 25 ml of chloroform, and the mixture was stirred and reacted under reflux for 4 hours, and then concentrated. did. The residue is then dissolved in 50 ml of acetone and 19.6 g of 4-chloro-2-trifluoromethylaniline in 150 ml of acetone.
(0.1 mol) and 9.0 g of sodium hydrogen carbonate
(0.11 mol), and the mixture was stirred and reacted under reflux for 2 hours. The reaction mixture was concentrated and then extracted with toluene. Next, the toluene layer was washed with water, dried over anhydrous magnesium sulfate, and concentrated. N-Hexane was added to the residue solid, which was filtered and dried, and 29.2 g (yield 83%) of 5-
(4-Chloro-2-trifluoromethylanilinocarbonyl) pentanoic acid ethyl ester (2) was obtained. Melting point: 112-113 ° C

5- (4-chloro-2-trifluoromethyl)
Synthesis of luanilinocarbonyl) pentanoic acid (3) Ethyl 5- (4-chloro-2-trifluoromethylanilinocarbonyl) pentanoate (17.6 g, 50 mmol) was dissolved in 200 ml of ethanol. To this solution was added 10 g (250 mmol) of sodium hydroxide dissolved in 80 ml of water, and the mixture was stirred and reacted at room temperature for 1 hour. The reaction mixture was concentrated and the residue was
And diluted to pH 6 with dilute hydrochloric acid. The precipitated crystals were collected by filtration and washed sequentially with water and hexane. Let this dry,
12.6 g (yield 78%) of 5- (4-chloro-2-trifluoromethylanilinocarbonyl) pentanoic acid (3) was obtained. Melting point: 143-145 ° C

5- (4-chloro-2-trifluoromethyl)
Luanilinocarbonyl) pentanoic acid benzyl ester
Synthesis of (4) 5- (4-chloro-2-trifluoromethylanilinocarbonyl) pentanoic acid (3) in 50 ml of chloroform
9.0 g (28 mmol) and 6 g of thionyl chloride (5
0 mmol), and the mixture was stirred and reacted under reflux for 2 hours, and then concentrated. Next, this residue and 3.3 g (28 mmol) of benzyl alcohol were dissolved in 120 ml of toluene. 3.3 g of triethylamine (28 mm
ol) was added dropwise at 10-20 ° C. under ice-water cooling, and the mixture was stirred and reacted at room temperature for 4 hours. To the reaction mixture was added 150 ml of ethyl acetate, and the organic layer was washed with water and dried over anhydrous magnesium sulfate. Concentrated. N-Hexane was added to the residue solid, which was filtered and dried, and 6.8 g (yield 59%) of 5-
(4-Chloro-2-trifluoromethylanilinocarbonyl) pentanoic acid benzyl ester (4) was obtained. Melting point: 94-95 ° C

6- (4-chloro-2-trifluoromethyl)
Ruphenyl) imino-6- (imidazol-1-yl)
Synthesis of benzyl hexanoate (5) 2.3 g (5.6 mmol) of benzyl 5- (4-chloro-2-trifluoromethylanilinocarbonyl ) pentanoate (4) in 6 ml of chloroform and 1. 3 g (6.3 mmol) was added, and the mixture was stirred and reacted under reflux for 1 hour, and then concentrated. Next, this residue was dissolved in 4 ml of chloroform, 0.42 g (6.2 mmol) of imidazole was added to the solution, and the mixture was stirred at 50-60 ° C for 30 minutes. 0.65 g of triethylamine
(6.4 mmol) at 5-10 ° C. under ice-water cooling,
Stir at 50-60 ° C for 30 minutes. 30 ml of chloroform was added to the reaction mixture, and the chloroform layer was washed with water.
Dried over anhydrous magnesium sulfate and concentrated. The residue was purified by silica gel chromatography (n-hexane: ethyl acetate = 3: 2) to obtain 1.1 g (42% yield) of 6-.
(4-Chloro-2-trifluoromethylphenyl) imino-6- (imidazol-1-yl) hexanoic acid benzyl ester (5) was obtained.

6- (4-chloro-2-trifluoromethyl)
Ruphenyl) imino-6- (imidazol-1-yl)
Synthesis of hexanoic acid (6) 6- (4-chloro-2-trifluoromethylphenyl) imino-6- (imidazole-1) was added to 10 ml of ethanol.
-Yl) hexanoic acid benzyl ester (5) 0.8 g
(1.7 mmol) and 50 mg of 10% palladium carbon were added, and hydrogen gas was blown into this mixture at room temperature with stirring for 15 hours. The reaction mixture was filtered and the filtrate was concentrated. The residue is subjected to silica gel chromatography (n-hexane: ethyl acetate: methanol = 1).
0: 10: 1) and 0.3 g (47% yield) of 6
Thus,-(4-chloro-2-trifluoromethylphenyl) imino-6- (imidazol-1-yl) hexanoic acid (6) was obtained.

¹ H-NMR (DMSO-D6, ppm) 1.64 (4H, m) 2.23 (2H, t) 2.66 (2H, t) 6.85 (1H, d) 7.12 ( 1H, s) 7.53 (1H, dd) 7.61 (1H, s) 7.65 (1H, d) 8.22 (1H, s) MS m / z: 373

Example 2 Preparation of antigen for immunization A conjugate of a triflumizole derivative and KLH was prepared as an immunogen by the mixed acid anhydride method as follows.

7 mg of the triflumizole derivative prepared in Example 1 was dissolved in 0.7 ml of anhydrous dioxane, cooled to 10-12 ° C., and 4 μl of tri-N-butylamine and 2.4 μl of isobutyl chloroformate were added. Then, the mixture was stirred at 10-12 ° C for 30 minutes (hereinafter referred to as “Solution A”).

[0094] On the other hand, the KLH distilled water 1ml dissolved 20 mg, 0.5% NaHCO _3, it was dialyzed overnight pH9.4 as an external solution. After the dialysis, the solution A was slowly added to 1.5 ml of the supernatant obtained by centrifugation at 3000 rpm for 30 minutes. 4
After reacting at 2 ° C. for 2 hours, one spatula of glycine was added, and the mixture was further stirred at 4 ° C. for 30 minutes to terminate the reaction. This reaction solution was 145 mM NaCl
It was dialyzed for one week in -10 mM PBS (pH 7.4) to obtain an antigen for immunization. The triflumizole-KLH conjugate thus obtained was used as an antigen for immunization.

Example 3 Preparation of Antigen for Screening A triflumizole derivative-BSA conjugate was obtained as a screening antigen in the same manner as in Example 2.

Example 4 Immunization Mice were immunized with the triflumizole derivative-KLH conjugate obtained in Example 2 as an antigen for immunization. 100 μg of immunizing antigen was added to PBS 10
After dissolving in 0 μl and mixing with an equal volume of complete Freund's adjuvant, Balb / c mice were inoculated. Seventeen days later, mice were boosted with the immunizing antigen prepared using Freund's incomplete adjuvant in the same manner as described above. Further, 41 days later, mice were boosted with an immunizing antigen dissolved in PBS.

Example 5 Measurement with Antiserum A solution of a triflumizole derivative-BSA conjugate (0.1
μg / ml) was coated on a 96-well plate at 50 μl / well. After washing, after blocking with 4-fold diluted Block Ace (“Block Ace”: Dainippon Pharmaceutical, code No. UK-25B), an antiserum diluent and various concentrations of triflumizole or a similar compound are contained. Mix equal amounts with 10% methanol solution,
100 μl thereof was put in a well and reacted at 37 ° C. for 1 hour. After completion of the reaction, 0.05% Tween 20-PB
After washing once with S, the peroxidase-conjugated anti-mouse-IgG goat antibody (C
Appel) (50 μl) was added to each well, and 3
The reaction was performed at 7 ° C. for 1 hour. After the reaction is completed, 0.0
Wash twice with 5% Tween 20-PBS, 0.4m
g / ml OPD and 0.05 M phosphate citrate buffer (pH 4.5) containing 0.04% hydrogen peroxide
0 μl was added to each well and left at room temperature for 20 minutes to develop color. After the reaction, 100 μl of 2N sulfuric acid was added to each well to stop the reaction, and the absorbance at 490 nm was measured.

Example 6 Preparation of Hybridoma Cells Following Example 4, spleen cells of a mouse with increased anti-triflumizole antibody activity in serum and mouse myeloma cells (P3U1) were cultured by electrofusion. Fusion was performed.
Antibody activity against triflumizole was examined for the culture supernatant in which cell proliferation was observed by the following method. Triflumizole derivative-BSA conjugate solution (0.1 μg / m
l) was coated at 50 μl / well into a 96-well plate. After washing, after blocking with Block Ace diluted 4 times, equal amounts of the culture supernatant and various concentrations of 10% methanol solution containing triflumizole or its analogous compound are mixed, and 100 μl of the mixture is placed in a well. At 37 ° C. for 1 hour. After the completion of the reaction, 0.
After washing once with 05% Tween 20-PBS, PB
Peroxidase-conjugated anti-mouse IgG goat antibody (Cappel) diluted 5000-fold with S
The reaction was carried out at 37 ° C. for 1 hour in each well. Further, after the reaction was completed, 2% in 0.05% Tween 20-PBS.
After multiple washes, 0.4 mg / ml OPD and 0.04
100 μl of 0.05 M phosphate citrate buffer (pH 4.5) containing 5% hydrogen peroxide was added to each well, and left at room temperature for 20 minutes to develop color. After the reaction, 2N sulfuric acid 10
After adding 0 μl to each well to stop the reaction,
The absorbance at nm was measured, and those having specific antibody activity were selected.

Next, the cells in the selected wells were subjected to cell cloning using the limiting dilution method. As a result, a hybridoma cell line producing an anti-triflumizole antibody was cloned. Among them, TFZ6-12 was deposited on February 4, 1997 with accession number FERM P-16058.
Was deposited with the Institute of Biotechnology, National Institute of Advanced Industrial Science and Technology (〒 1-3 1-3 Higashi, Tsukuba, Ibaraki Prefecture, 305).

Example 7 Tolflumizole derivative and HR
Preparation of conjugate with P A conjugate of the triflumizole derivative and HRP prepared in Example 1 was prepared by the mixed anhydride method similar to that in Example 2. After dissolving 1 mg of the triflumizole derivative in 0.2 ml of anhydrous dioxane, 0.1 ml of tri-N-butylamine was dissolved.
5 μl and 0.3 μl of isobutyl chloroformate were added, and 1
Stirred at 0-12 ° C for 30 minutes. (Hereafter, this is referred to as "B
And liquid ") On the other hand, a 0.5% NaHCO ₃ was dissolved HRP5mg solution 1ml adjusted to pH9.4 with NaOH, and added dropwise to solution B therein. The mixture was stirred at 4 ° C. for 2 hours, glycine was further added, and the mixture was stirred for 30 minutes to complete the reaction. The reaction was dialyzed against PBS to give purified H.
An RP-linked triflumizole derivative was obtained.

Example 8 By direct competitive inhibition ELISA
Measurement of Triflumizole Hybridoma cells (TFZ6-1) obtained in Example 6
2) was transplanted into the abdominal cavity of a mouse, and ascites obtained 10 to 15 days later was collected, a monoclonal antibody was fractionated by ammonium sulfate fractionation, and triflumizole was measured by the following test method.

Each monoclonal antibody solution (5 μl
g / ml) in a 96-well plate at 100 μl / well, allowed to stand at 4 ° C. overnight, blocked with 4-fold diluted Block Ace the next day, and then diluted with Triflumizole and the moderately diluted solution prepared in Example 7. A 10% methanol-PBS solution containing the HRP-bound triflumizole derivative was added at 50 μl / well, and left at 37 ° C. for 1 hour. After completion of the reaction, the cells were washed twice with 0.05% Tween 20-PBS, and then 0.4 mg / ml OPD and 0.04%
0.05M phosphate citrate buffer containing hydrogen peroxide (pH
4.5) was added to each well in an amount of 100 μl, and the mixture was added at room temperature for 20 μl.
Allowed to stand for a minute for color development. After the reaction, 100 µl of 2N sulfuric acid
Was added to each well to stop the reaction, and the absorbance at 490 nm was measured. The result is shown in FIG. In the direct competitive inhibition ELISA method, triflumizole can be measured, and the measurement range is 0.1-100 ng / m2.
l.

Example 9 Evaluation of Monoclonal Antibody The monoclonal antibody TFZ6-12 produced by the cloned hybridoma TFZ6-12 derived from a triflumizole derivative was used for the production of triflumizole and other antibodies using the same method as in Example 8. The reactivity to similar azole compounds was examined. The result is shown in FIG. As shown in FIG. 2, this antibody has a very high specificity, reacts only with triflumizole, and does not react with other similar azole compounds such as diniconazole, imazalil, and diclobutrazole. Monoclonal antibody TFZ6-
No. 12 was able to measure the amount of triflumizole in the range of 0.1-100 ng / ml by a direct competitive ELISA method.

[Brief description of the drawings]

FIG. 1 shows the monoclonal antibody TFZ6 of the present invention.
Fig. 3 shows the measurement of triflumizole by the direct competitive inhibition ELISA method of -12.

FIG. 2 shows the measurement of triflumizole and other similar azole compounds by the direct competitive inhibition ELISA of the monoclonal antibody TFZ6-12.

──────────────────────────────────────────────────の Continued on the front page (51) Int.Cl. ⁶ Identification symbol FI G01N 33/577 C12N 5/00 B // (C12N 5/10 C12R 1:91) (C12P 21/08 C12R 1:91) ( 72) Inventor Yoshitaka Taniguchi 1-27-14, Hamamatsucho, Minato-ku, Tokyo Inside the Institute for Environmental Immunity Technology (72) Inventor Kazuaki Watanabe 1-27-14, Hamamatsucho, Minato-ku, Tokyo Immune Technology Research Institute

Claims (9)

[Claims] (1) The following formula (1): [In the formula (1), n is an integer of 1-10] A compound having a structure represented by the following formula: 2. A conjugate of the compound according to claim 1 with a polymer compound or a labeling substance. 3. An antigen is prepared by binding the compound according to claim 1 with a polymer compound, and the antigen is used to obtain the following formula (2): A method for producing an antibody or a fragment thereof reactive to a compound of the formula (2), characterized by producing an antibody reactive to a compound having a structure represented by the formula: 4. An antibody or a fragment thereof, which is produced by using the conjugate according to claim 2 as an antigen and which is reactive with the compound of the formula (2). 5. The antibody or fragment thereof according to claim 4, which is a monoclonal antibody. 6. The antibody or fragment thereof according to claim 4, which is TFZ6-12. 7. A hybridoma producing the antibody or fragment thereof according to any one of claims 4 to 6. 8. The hybridoma according to claim 7, which has been deposited under accession number FERM P-16058. 9. A compound represented by the formula (2), wherein the compound according to claim 1 and / or the antibody or fragment thereof according to any one of claims 4 to 6 is used. A method for immunological measurement of a compound.